Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
US Market
Holding GLUE?
Track your performance easily

Monte Rosa Therapeutics (GLUE) Ownership - Who Owns Monte Rosa Therapeutics?

254 Followers

Monte Rosa Therapeutics (GLUE) Ownership Overview

21.78%20.22%0.03%7.37%50.60%
21.78% Insiders
0.03% Other Institutional Investors
7.37% ETFs
50.60% Public Companies and
Individual Investors
The ownership structure of Monte Rosa Therapeutics (GLUE) stock is a mix of institutional, retail, and individual investors. Approximately 27.62% of the company’s stock is owned by Institutional Investors, 21.78% is owned by Insiders, and 50.60% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 30, 2024
xxxxxxxxxxxxx
$1489973
Sep 24, 2024
xxxxxxxxxxxxx
$7384330
Sep 13, 2024
xxxxxxxxxxxxx
$3404761
Jul 09, 2024
xxxxxxxxxxxxx
$6166

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
7,692,298Insider12.53%68,461,452
5,652,922Insider9.21%50,311,006
4,916,095Institution8.01%43,753,246
3,418,333Institution5.57%30,423,164
2,441,190Institution3.98%21,726,591
2,209,590Institution3.60%19,665,351
1,523,456Institution2.48%13,558,758
1,472,331Institution2.40%13,103,746
1,336,920Institution2.18%11,898,588
982,758Institution1.60%8,746,546

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
3,418,333Institution5.57%30,423,164
2,209,590Institution3.60%19,665,351
1,336,920Institution2.18%11,898,588
982,758Institution1.60%8,746,546
952,900Institution1.55%8,480,810
868,208Institution1.41%7,727,051
852,355Institution1.39%7,585,960
416,599Institution0.68%3,707,731
352,859Institution0.57%3,140,445
145,799Institution0.24%1,297,611

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,027,710Institution1.67%9,146,619
1,350,106Institution2.20%7,155,562
718,994Institution1.17%3,810,668
385,695Institution0.63%3,432,686
218,704Institution0.36%1,858,984
188,119Institution0.31%997,031
95,513Institution0.16%850,066
152,930Institution0.25%810,529
61,503Institution0.10%522,776
60,941Institution0.10%376,006

FAQ

Who Owns Monte Rosa Therapeutics (GLUE)?
According to the latest TipRanks data, approximately 0.03% of the company's stock is held by institutional investors, 21.78% is held by insiders, and 50.60% is held by retail investors.
    What percentage of Monte Rosa Therapeutics (GLUE) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 0.03% of Monte Rosa Therapeutics (GLUE) stock is held by institutional investors.
      What percentage of Monte Rosa Therapeutics (GLUE) stock is held by retail investors?
      According to the latest TipRanks data, approximately 50.60% of Monte Rosa Therapeutics (GLUE) stock is held by retail investors.
        Who owns the most shares of Monte Rosa Therapeutics (GLUE)?
        Ali Behbahani owns the most shares of Monte Rosa Therapeutics (GLUE).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis